PT106679B - Formulações tópicas de tetraciclinas, sua preparação e usos - Google Patents

Formulações tópicas de tetraciclinas, sua preparação e usos Download PDF

Info

Publication number
PT106679B
PT106679B PT106679A PT10667912A PT106679B PT 106679 B PT106679 B PT 106679B PT 106679 A PT106679 A PT 106679A PT 10667912 A PT10667912 A PT 10667912A PT 106679 B PT106679 B PT 106679B
Authority
PT
Portugal
Prior art keywords
formulation
topical
minocycline
suspension
microns
Prior art date
Application number
PT106679A
Other languages
English (en)
Portuguese (pt)
Other versions
PT106679A (pt
Inventor
Mohammad Salman
Arturo Angel
Vijaya Swaminathan
Original Assignee
Hovione Farmaciencia Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49620233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT106679(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hovione Farmaciencia Sa filed Critical Hovione Farmaciencia Sa
Priority to PT106679A priority Critical patent/PT106679B/pt
Priority to CN201380068453.1A priority patent/CN104902875B/zh
Priority to PCT/GB2013/052939 priority patent/WO2014083311A1/en
Priority to NZ708824A priority patent/NZ708824A/en
Priority to CA2895395A priority patent/CA2895395C/en
Priority to HUE13792728A priority patent/HUE034932T2/en
Priority to ES13792728.1T priority patent/ES2645449T3/es
Priority to MX2015006632A priority patent/MX355174B/es
Priority to PL13792728T priority patent/PL2925293T3/pl
Priority to SG11201504145PA priority patent/SG11201504145PA/en
Priority to EP13792728.1A priority patent/EP2925293B1/en
Priority to AU2013350941A priority patent/AU2013350941B2/en
Priority to RU2015122786A priority patent/RU2639591C2/ru
Priority to US14/074,868 priority patent/US9592246B2/en
Priority to NO13792728A priority patent/NO2925293T3/no
Priority to BR112015012162-4A priority patent/BR112015012162B1/pt
Priority to DK13792728.1T priority patent/DK2925293T3/da
Priority to KR1020157017068A priority patent/KR102235922B1/ko
Priority to JP2015543515A priority patent/JP6444308B2/ja
Publication of PT106679A publication Critical patent/PT106679A/pt
Publication of PT106679B publication Critical patent/PT106679B/pt
Priority to IL239022A priority patent/IL239022B/en
Priority to ZA2015/04369A priority patent/ZA201504369B/en
Priority to US15/457,809 priority patent/US10213443B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT106679A 2012-11-27 2012-11-27 Formulações tópicas de tetraciclinas, sua preparação e usos PT106679B (pt)

Priority Applications (22)

Application Number Priority Date Filing Date Title
PT106679A PT106679B (pt) 2012-11-27 2012-11-27 Formulações tópicas de tetraciclinas, sua preparação e usos
JP2015543515A JP6444308B2 (ja) 2012-11-27 2013-11-08 テトラサイクリン局所製剤、その調製及び使用
EP13792728.1A EP2925293B1 (en) 2012-11-27 2013-11-08 Tetracycline topical formulations, preparation and uses thereof
RU2015122786A RU2639591C2 (ru) 2012-11-27 2013-11-08 Тетрациклиновые композиции для местного применения, их получение и применение
NZ708824A NZ708824A (en) 2012-11-27 2013-11-08 Tetracycline topical formulations, preparation and uses thereof
CA2895395A CA2895395C (en) 2012-11-27 2013-11-08 Tetracycline topical formulations, preparation and uses thereof
HUE13792728A HUE034932T2 (en) 2012-11-27 2013-11-08 Tetracycline topical formulations, preparation and uses thereof
ES13792728.1T ES2645449T3 (es) 2012-11-27 2013-11-08 Formulaciones tópicas de tetraciclina, preparación y usos de las mismas
MX2015006632A MX355174B (es) 2012-11-27 2013-11-08 Formulaciones de uso topico de tetraciclina, preparaciones y usos de las mismas.
PL13792728T PL2925293T3 (pl) 2012-11-27 2013-11-08 Formulacje tetracykliny do stosowania miejscowego, ich przygotowanie i zastosowania
SG11201504145PA SG11201504145PA (en) 2012-11-27 2013-11-08 Tetracycline topical formulations, preparation and uses thereof
CN201380068453.1A CN104902875B (zh) 2012-11-27 2013-11-08 四环素局部制剂、其制备及用途
AU2013350941A AU2013350941B2 (en) 2012-11-27 2013-11-08 Tetracycline topical formulations, preparation and uses thereof
PCT/GB2013/052939 WO2014083311A1 (en) 2012-11-27 2013-11-08 Tetracycline topical formulations, preparation and uses thereof
US14/074,868 US9592246B2 (en) 2012-11-27 2013-11-08 Tetracycline topical formulations, preparation and uses thereof
NO13792728A NO2925293T3 (OSRAM) 2012-11-27 2013-11-08
BR112015012162-4A BR112015012162B1 (pt) 2012-11-27 2013-11-08 formulação de suspensão tópica e formulação de suspensão de minociclina tópica para usar no tratamento de acne vulgaris
DK13792728.1T DK2925293T3 (da) 2012-11-27 2013-11-08 Topiske tetracyclinformuleringer, fremstilling og anvendelser deraf
KR1020157017068A KR102235922B1 (ko) 2012-11-27 2013-11-08 테트라사이클린 국소 제제, 제조방법, 및 이의 용도
IL239022A IL239022B (en) 2012-11-27 2015-05-26 Tetracycline topical formulations, preparation and uses thereof
ZA2015/04369A ZA201504369B (en) 2012-11-27 2015-06-17 Tetracycline topical formulations, preparation and uses thereof
US15/457,809 US10213443B2 (en) 2012-11-27 2017-03-13 Tetracycline topical formulations, preparation and uses thereof in treating an ocular condition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PT106679A PT106679B (pt) 2012-11-27 2012-11-27 Formulações tópicas de tetraciclinas, sua preparação e usos

Publications (2)

Publication Number Publication Date
PT106679A PT106679A (pt) 2014-05-27
PT106679B true PT106679B (pt) 2015-03-25

Family

ID=49620233

Family Applications (1)

Application Number Title Priority Date Filing Date
PT106679A PT106679B (pt) 2012-11-27 2012-11-27 Formulações tópicas de tetraciclinas, sua preparação e usos

Country Status (21)

Country Link
US (2) US9592246B2 (OSRAM)
EP (1) EP2925293B1 (OSRAM)
JP (1) JP6444308B2 (OSRAM)
KR (1) KR102235922B1 (OSRAM)
CN (1) CN104902875B (OSRAM)
AU (1) AU2013350941B2 (OSRAM)
BR (1) BR112015012162B1 (OSRAM)
CA (1) CA2895395C (OSRAM)
DK (1) DK2925293T3 (OSRAM)
ES (1) ES2645449T3 (OSRAM)
HU (1) HUE034932T2 (OSRAM)
IL (1) IL239022B (OSRAM)
MX (1) MX355174B (OSRAM)
NO (1) NO2925293T3 (OSRAM)
NZ (1) NZ708824A (OSRAM)
PL (1) PL2925293T3 (OSRAM)
PT (1) PT106679B (OSRAM)
RU (1) RU2639591C2 (OSRAM)
SG (1) SG11201504145PA (OSRAM)
WO (1) WO2014083311A1 (OSRAM)
ZA (1) ZA201504369B (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
EP2482788B1 (en) 2009-10-02 2022-12-14 Journey Medical Corporation Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
CA2970502A1 (en) * 2014-12-12 2016-06-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
US10512608B2 (en) 2015-02-25 2019-12-24 Sun Pharma Advanced Research Company Ltd. Nanoparticulate composition
AU2016235237B2 (en) 2015-03-23 2021-03-11 BioPharmX, Inc. Pharmaceutical tetracycline composition for dermatological use
CN105380900B (zh) * 2015-11-25 2018-05-29 徐州医学院 一种治疗痤疮的纳米磁疗外用凝胶及其制备方法和应用
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
FR3064482B1 (fr) * 2017-04-03 2020-11-13 Horus Pharma Composition topique de doxycycline
MX2020004187A (es) * 2017-10-24 2020-09-21 Glenmark Pharmaceuticals Ltd Composicion farmaceutica topica de adapaleno y minociclina.
EP3717655A1 (en) 2017-11-28 2020-10-07 c-LEcta GmbH Method for producing trehalose employing a trehalose phosphorylase variant
WO2019135166A1 (en) 2018-01-07 2019-07-11 Dr. Reddy's Laboratories Ltd. Minocycline for treating inflammatory skin conditions
JP7506679B2 (ja) 2018-10-29 2024-06-26 フラウンホーファー－ゲゼルシャフト・ツール・フェルデルング・デル・アンゲヴァンテン・フォルシュング・アインゲトラーゲネル・フェライン 持続性活性を有するテトラサイクリン複合体
US11202788B2 (en) 2019-08-22 2021-12-21 Nanopharmaceutics, Inc. Topical doxycycline hydrogel with improved long-term stability
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
WO2022043457A1 (en) 2020-08-27 2022-03-03 Hovione Scientia Limited Methods and compositions for treating rosacea
WO2022090302A1 (en) * 2020-10-28 2022-05-05 Hovione Scientia Limited Methods and compositions for treating meibomian gland dysfunction, dry eye disease, and related disorders
CN115463091B (zh) * 2022-10-27 2023-04-07 新基元(北京)医药科技有限公司 一种改善稳定性的米诺环素泡沫剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275218A1 (en) * 2003-08-04 2006-12-07 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
GB2474930A (en) * 2009-10-02 2011-05-04 Foamix Ltd Topical composition comprising a tetracycline
WO2011138678A2 (en) * 2010-05-04 2011-11-10 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB769274A (en) * 1954-04-22 1957-03-06 Pfizer Therapeutic preparations of tetracycline antibiotics in oil
GB1581335A (en) 1976-07-05 1980-12-10 Leo Pharm Prod Ltd 16-s-acyl derivatives of fusidic acid
US4505896A (en) 1979-04-19 1985-03-19 Elorac, Ltd. Method of treating acne vulgaris and composition
JPS5788115A (en) * 1980-10-06 1982-06-01 Miles Lab Stable non-aqueous solution of tetracycline antibiotic salt
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
US5874479A (en) 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US6113921A (en) 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
US5905092A (en) 1994-09-27 1999-05-18 Virotex Corporation Reel/Frame Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
EP0884997B1 (en) * 1996-02-16 2002-06-05 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a sulfur compound
JPH09255578A (ja) * 1996-03-22 1997-09-30 Sekisui Chem Co Ltd 感染性皮膚疾患治療用外用剤
US5834008A (en) 1996-09-19 1998-11-10 U.S. Biomaterials Corp. Composition and method for acceleration of wound and burn healing
US6433068B1 (en) * 1997-03-07 2002-08-13 David S. Morrison Hydrocarbon gels as suspending and dispersing agents and products
PT1676579E (pt) * 1998-05-08 2009-03-24 Univ Miami Utilização de tetraciclinas sub-antimicrobianas para o tratamento de rosácea ocular
US20030007939A1 (en) 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
CN1320046A (zh) * 1999-07-12 2001-10-31 三得利株式会社 局部给药的药用组合物
US6946118B1 (en) 1999-09-14 2005-09-20 Orapharma, Inc. Formulations for treating or preventing mucositis
US6667045B2 (en) 1999-10-01 2003-12-23 Joseph Scott Dahle Topical applications for skin treatment
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US20020010162A1 (en) 2000-03-02 2002-01-24 Raul Fleischmajer Treatment of psoriasis with matrix metalloproteinase inhibitors
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
JP4653282B2 (ja) * 2000-05-23 2011-03-16 昭和薬品化工株式会社 ミノサイクリン含有組成物
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
AU2002256092C1 (en) * 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
AU2002317053B2 (en) 2001-07-27 2004-08-05 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
KR20050026401A (ko) 2002-06-17 2005-03-15 비큐론 파마세티컬스 인코포레이티드 여드름 치료를 위한 ｇｅ 2270 인자 ａ3의 아미드유도체의 용도
US20040076699A1 (en) * 2002-07-15 2004-04-22 Chaudhuri Ratan K. Topical anhydrous delivery system
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
KR100738264B1 (ko) 2003-06-11 2007-07-12 더 프록터 앤드 갬블 캄파니 예비형성된 하이드로겔 제품을 포함하는 사용시-제조 장치
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US7241746B2 (en) 2003-08-06 2007-07-10 Regena Therapeutics, Lc Method and composition for treating periodontal disease
WO2006035320A2 (en) 2004-09-27 2006-04-06 Jan De Rijk Methods and compositions for treatment of water
US7531164B2 (en) 2005-10-21 2009-05-12 Duke University Preventing bacterial or viral infectivity and composition containing infection preventing additive
GB2432529B (en) 2005-11-25 2008-04-23 Univ Feng Chia Antimicrobial compositions and wound dressings
JP4959991B2 (ja) * 2006-03-03 2012-06-27 株式会社日本点眼薬研究所 トラニラストまたはその薬理学的に許容される塩を含有する懸濁性医薬組成物
US20080188445A1 (en) 2007-02-02 2008-08-07 Warner Chilcott Company Inc. Tetracycline compositions for topical administration
WO2008097851A1 (en) * 2007-02-02 2008-08-14 Warner Chilcott Company, Inc. Tetracycline compositions for topical administration
AU2008219600A1 (en) 2007-02-28 2008-09-04 Aciex Therapeutics, Inc. Methods and compositions for normalizing meibomian gland secretions
KR20090122994A (ko) * 2007-03-23 2009-12-01 몰레큘러 리서치 센터, 인크. 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도
HRP20100699T1 (hr) 2007-07-25 2011-01-31 Ixodes Gmbh Topikalni antibioticki sastav za prevenciju lajmske bolesti
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
GB0800145D0 (en) * 2008-01-04 2008-02-13 Reckitt Benckiser Uk Ltd Skincare treatment
KR20100127300A (ko) * 2008-03-28 2010-12-03 안게스 엠지 인코포레이티드 전사 인자 디코이를 유효 성분으로 하는 외용제 조성물
US9149660B2 (en) * 2008-04-29 2015-10-06 Hair Systems Inc. Composition and method for cream bleach product
US20100029765A1 (en) 2008-07-30 2010-02-04 Ranbaxy Labortories Limited Topical aqueous composition comprising tretinoin
CA2734687A1 (en) * 2008-08-18 2010-02-25 Nanotherapeutics, Inc. Topical hydrogel composition
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
PT104644B (pt) 2009-06-26 2012-11-06 Hovione Farmaciencia S A Formulação tópica contendo uma tetraciclina e método de tratamento de infecções cutâneas usando a mesma
US9155915B2 (en) 2009-07-27 2015-10-13 Dermadoctor, Inc. Moisturizing retinol composition
EP2482788B1 (en) 2009-10-02 2022-12-14 Journey Medical Corporation Topical tetracycline compositions
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US20120076766A1 (en) 2010-04-21 2012-03-29 Phillips D Howard Topical drug delivery system with dual carriers
PT105116B (pt) 2010-05-14 2012-10-16 Hovione Farmaciencia S A Novas partículas de tetraciclina e agente protector.
BRPI1002601E2 (pt) 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
US20120093876A1 (en) 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
CA2719512A1 (en) 2010-11-01 2012-05-01 Stiefel Research Australia Pty Ltd Polymeric topical compositions
EP2667945A1 (en) * 2011-01-24 2013-12-04 Anterios, Inc. Oil compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275218A1 (en) * 2003-08-04 2006-12-07 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
GB2474930A (en) * 2009-10-02 2011-05-04 Foamix Ltd Topical composition comprising a tetracycline
WO2011138678A2 (en) * 2010-05-04 2011-11-10 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof

Also Published As

Publication number Publication date
CA2895395A1 (en) 2014-06-05
NZ708824A (en) 2019-01-25
US20140147504A1 (en) 2014-05-29
US10213443B2 (en) 2019-02-26
ZA201504369B (en) 2017-01-25
US9592246B2 (en) 2017-03-14
EP2925293B1 (en) 2017-08-02
IL239022A0 (en) 2015-07-30
MX355174B (es) 2018-04-09
DK2925293T3 (da) 2017-11-06
PT106679A (pt) 2014-05-27
HUE034932T2 (en) 2018-03-28
CA2895395C (en) 2021-04-06
SG11201504145PA (en) 2015-07-30
US20170182071A1 (en) 2017-06-29
CN104902875A (zh) 2015-09-09
RU2015122786A (ru) 2017-01-10
IL239022B (en) 2020-11-30
KR20150104102A (ko) 2015-09-14
MX2015006632A (es) 2016-02-17
KR102235922B1 (ko) 2021-04-05
CN104902875B (zh) 2018-04-03
NO2925293T3 (OSRAM) 2017-12-30
JP2016500095A (ja) 2016-01-07
AU2013350941A1 (en) 2015-07-16
AU2013350941B2 (en) 2018-04-26
PL2925293T3 (pl) 2017-12-29
EP2925293A1 (en) 2015-10-07
ES2645449T3 (es) 2017-12-05
RU2639591C2 (ru) 2017-12-21
BR112015012162B1 (pt) 2021-02-23
JP6444308B2 (ja) 2018-12-26
WO2014083311A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
US10213443B2 (en) Tetracycline topical formulations, preparation and uses thereof in treating an ocular condition
Patil et al. A review on topical gels as drug delivery system
ES2253423T3 (es) Formulacion de un ester de testosterona para uso humano.
CN108289846B (zh) 脂质体的制备方法
WO2017120586A1 (en) Formulations for treating bladder cancer
CN108159055A (zh) 治疗乳腺癌的长效递药系统、其制备方法及应用
CN102327214A (zh) 一种百里香酚纳米药物及其制备方法
WO2013143300A1 (zh) 氟维司群或其衍生物缓释制剂及其制备方法
JP2016188261A (ja) ヒストンデアセチラーゼ阻害薬のための医薬製剤
WO2004096261A1 (es) Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante
AU2023244508A1 (en) Mirabegron formulation
CN101632683A (zh) 一种替尼泊甙药物组合物及其制备方法
Muslim et al. Perspective Impact of Gelling Agents on the Mechanistic Behavior for the Topical Delivery of Flufenamic Acid Nano-Ethosomal Dispersion
ES2717299T3 (es) Una combinación de unidades de dosificación para su uso en el tratamiento del parto prematuro
BAJAJ et al. Evaluation of antiarthritic activity of aceclofenac amphiphilogels against Freund's complete adjuvant induced arthritis in rats.
Anupriya et al. Chemical Penetration Enhancers for Transdermal Drug Delivery System
Rajesh et al. Formulation and in vitro evaluation of naloxone transdermal patches
Suriaprabha et al. Effect of carbopol gel in stable liposomes and their enhanced antipyretic effect
Shete et al. Formulation and In-vitro, In-vivo Evaluation of Itraconazole and Itraconazole Co-Crystals Loaded Glyceryl Monooleate Based Liquid Crystalline Gel
CN106265808A (zh) 鹅不食草油鼻用微乳温敏凝胶释药系统及其制备方法
CN104138351A (zh) 他克莫司非水凝胶
Saleem et al. Preparation and characterization of a unani transdermal antiemetic emulgel, A novel approach
Nagaraju et al. FORMULATION AND EVALUATION TRANSDERMAL DRUG DELIVERY SYSTEM OF GEMIFLOXACIN
Hespeler et al. Novel delivery system smartPearls–efficient delivery system for antioxidants in anti-pollution

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 20131220

FG3A Patent granted, date of granting

Effective date: 20150320